DERM Stock Forecast & Price Target

Journey Medical Corp has demonstrated significant growth in payer access, increasing coverage from approximately 30% of commercial lives in May to around 65% by July, which equates to over 100 million lives. Additionally, the adoption of prescribers has surged, rising from around 660 in the first quarter to over 1,800 by the second quarter, indicating robust traction in the market. Furthermore, established brand value, especially for products like Accutane, enhances customer retention and supports the company's ability to maintain market share in the dermatological pharmaceutical sector.

Journey Medical Corp faces a negative outlook primarily due to a significant decline in Accutane prescriptions, which fell to approximately 66,000 in the first quarter of 2025 from 93,000 in the same period of 2024. The company also experiences key risks such as competitive pressure from both branded and generic rosacea treatments, and concerns regarding the slow uptake of Emrosi along with potential payer reimbursement challenges. Additionally, ongoing regulatory and clinical risks, coupled with the possibility of higher-than-expected cash burn, further complicate the company's financial stability and growth prospects.